Download PDF
Thromb Haemost 1986; 56(01): 053-056
DOI: 10.1055/s-0038-1661602
Original Article
Schattauer GmbH Stuttgart

Prophylaxis of Thromboembolic Disease and Platelet-Related Changes Following Total Hip Replacement: A Comparative Study of Aspirin and Heparin-Dihydroergotamine

M J Alfaro
The Service of Hematology, University of Navarra, Pamplona, Spain
,
J A Páramo
The Service of Hematology, University of Navarra, Pamplona, Spain
,
E Rocha
The Service of Hematology, University of Navarra, Pamplona, Spain
› Author Affiliations
Further Information

Publication History

Received 12 November 1985

Accepted 26 May 1986

Publication Date:
13 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

A prospective study involving 120 consecutive patients undergoing total hip replacement was performed to compare the effectiveness of aspirin (high and low dose) or a combination of heparin plus dihydroergotamine (heparin-DHE) in preventing isotopic and phlebographic deep vein thrombosis (DVT), and to evaluate their effect on postoperative platelet changes. Phlebographic DVT was demonstrated in 9 cases (30%) in control group, in 1 (3.3%) in aspirin (high-dose) group (p <0.01), in 1 (3.3%) in aspirin (low-dose) group (p <0.01) and in 5 (16.6%) in heparin-DHE group (p = NS). Aspirin was able to reduce the postoperative increase in circulating platelet aggregates, platelet factor 4 and p-thromboglobulin observed in control group. This study shows that aspirin is effective in the prevention of DVT for patients undergoing total hip replacement. Small aspirin dose (250 mg/day) represents an effective form of prophylaxis in these patients.

Keywords

Postoperative deep vein thrombosis - Aspirin - Heparin - dihydroergotamine
 

  • References

  • 1 Kakkar VV. Prevention of venous thromboembolism. Clin Haematol 1981; 10: 543-582
    PubMedGoogle Scholar
  • 2 International Multicentre trial. Prevention of fatal post-operative pulmonary embolism by low-doses of heparin. Lancet 1975; 2: 45-51
    PubMedGoogle Scholar
  • 3 Clagett GP, Salzman EW. Prevention of venous thromboembolism in surgical patients. N Engl J Med 1974; 290: 93-96
    CrossrefPubMedGoogle Scholar
  • 4 Sikorski JM, Hampson WG, Staddon GE. The natural history and etiology of deep vein thrombosis after total hip replacement. J Bone Joint Surg 1981; 63 B 171-177
    CrossrefPubMedGoogle Scholar
  • 5 Crawford WJ, Hillman F, Charnley J. Internal publication Wrightin-ton Centre for hip surgery. No 14. May 1968
    PubMedGoogle Scholar
  • 6 Morris GG, Mitchell J RA. Preventing venous thromboembolism in elderly patients with hip fractures. Studies of low dose heparin, dipyridamole, aspirin and flurbiprofen. Br Med J 1977; 1: 535-537
    PubMedGoogle Scholar
  • 7 Cooke ED, Dawson MHO, Ibbotson RM, Path M RC, Bowcock SD, Ainsworth ME, Pilcher MF. Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations. J Bone Joint Surg 1977; 59 A 496-500
    CrossrefPubMedGoogle Scholar
  • 8 Harris WH, Salzman EW, Athanasoulis C, Waltman AC, Baum S, DeSanctis RW. Comparison of warfarin, low molecular weight dextran, aspirin and subcutaneous heparin in prevention of venous thromboembolism following total hip replacement. J Bone Joint Surg 1974; 56 A: 1552-1562
    CrossrefPubMedGoogle Scholar
  • 9 Hampson W GJ, Harris FC, Lucas HK, Roberts PH, McCall IW, Jackson NC, Powell NL, Staddon GE. Failure of low dose heparin to prevent deep vein thrombosis after hip replacement arthroplasty. Lancet 1974; 2: 795-797
    PubMedGoogle Scholar
  • 10 Salzman EW, Harris WH, DeSanctis RW. Reduction in venous thromboembolism by agents affecting platelet function. N Engl J Med 1971; 284: 1287-1292
    CrossrefPubMedGoogle Scholar
  • 11 Jennings JJ, Harris WH, Sarmiento A. A clinical evaluation of aspirin prophylaxis of thromboembolic disease after total hip arthroplasty. J Bone Joint Surg 1976; 58 A: 926-928
    CrossrefPubMedGoogle Scholar
  • 12 Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, DeSanctis RW. Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med 1977; 297: 1246-1249
    CrossrefPubMedGoogle Scholar
  • 13 Kakkar VV, Stamatakis JD, Bentley PG, Lawrence D, Haas HA, Ward VP. Prophylaxis for postoperative deep-vein thrombosis. Synergistic effect of heparin and dihydroergotamine. JAMA 1979; 241: 39-42
    PubMedGoogle Scholar
  • 14 Schondorf TH, Weber U. Heparin prophylaxis combined with DHE or dextran in hip operations. Thromb Haemostas 1979; 42: 249 (Abstr)
    PubMedGoogle Scholar
  • 15 Gruber UF. Prevention of fatal postoperative pulmonary embolism by heparin dihydroergotamine or dextran 70. Br J Surg 1982; (Suppl. 69) 54-68
    PubMedGoogle Scholar
  • 16 Comerota AJ, Diserio FJ, Sasahara AA. Dihydroergotamine-heparin prophylaxis of DVT in total hip replacement patients: A multicentre trial. Thromb Haemostas 1985; 54: 99 (Abstr)
    PubMedGoogle Scholar
  • 17 Houghton GR, Papadakis EG, Rizza CR. Changes in blood coagulation during total hip replacement. Lancet 1978; 1: 1336-1338
    PubMedGoogle Scholar
  • 18 Paramo JA, Rocha E. Deep vein thrombosis and related platelet changes after total hip replacement. Haemostasis 1985; 15: 389-394
    PubMedGoogle Scholar
  • 19 Páramo JA, Alfaro MJ, Rocha E. Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor. Relationship to deep vein thrombosis and influence of prophylaxis. Thromb Haemostas 1985; 54: 713-716
    PubMedGoogle Scholar
  • 20 Morris GK. Preoperative prediction of postoperative deep vein thrombosis. Thromb Haemostas 1979; 41: 27-32
    PubMedGoogle Scholar
  • 21 Clayton JF, Anderson JA, McNicol GP. Preoperative prediction of postoperative deep vein thrombosis. Br Med J 1976; 2: 910-912
    CrossrefPubMedGoogle Scholar
  • 22 Kakkar VV. The diagnosis of deep vein thrombosis using the 125I-fibrinogen test. Arch Surg 1972; 104: 152
    CrossrefPubMedGoogle Scholar
  • 23 Wu KK, Hoak JC. A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 1974; 2: 924-926
    PubMedGoogle Scholar
  • 24 Bolton AE, Ludlam CA, Pepper DS, Moore S, Cash JD. A radioimmunoassay for platelet factor 4. Thromb Res 1976; 8: 51-58
    CrossrefPubMedGoogle Scholar
  • 25 Ludlam CA, Cash JD. Studies on the liberation of β-thromboglobulin from human platelets in vitro. Br J Haematol 1976; 33: 239-247
    CrossrefPubMedGoogle Scholar
  • 26 Dixon WJ. BMDP statistical software. University of California; Los Angeles: 1981
    Google Scholar
  • 27 Kakkar VV, Fok PJ, Murray W JG, Paes T, Merenstein D, Dodds R, Farrel R, Crellin RQ, Thomas EM, Morley TR, Price AJ. Heparin and dihydroergotamine prophylaxis against thromboembolism after hip arthroplasty. J Bone Joint Surg 1985; 67 B: 538-542
    PubMedGoogle Scholar
  • 28 Zahavi J, Kakkar VV. β-thromboglobulin: a specific marker of in vivo platelet release reaction. Thromb Haemostas 1980; 44: 23-29
    PubMedGoogle Scholar
  • 29 Kaplan KL, Owen J. Plasma levels of p-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981; 57: 199-202
    PubMedGoogle Scholar
  • 30 Salzman EW, Harris WH. Acetylsalicilic acid for prevention of venous thromboembolic disease in surgical patients. In: Acetylsalicilic acid: new uses for an old drug Barnett H JM, Hirsh J, Mustard JF. (eds). pp. 238-255 Raven Press; New York: 1982
  • 31 Stamatakis JD, Kakkar VV, Sagar S, Lawrence D, Nairn D, Bentley PG. Femoral vein thrombosis and total hip replacement. Br Med J 1977; 2: 223-225
    CrossrefPubMedGoogle Scholar
  • 32 Stamatakis JD, Kakkar VV, Lawrence D, Bentley PG. The origin of thrombi in the deep veins of the lower limb: a venographic study. Br J Surg 1978; 65: 449-451
    CrossrefPubMedGoogle Scholar